Blocking Mitochondrial Pyruvate Transport Alters Corneal Myofibroblast Phenotype: A New Target for Treating Fibrosis

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2023 Oct 23

PMID 37870848

Authors

Kye-Im Jeon

Ankita Kumar

Christine L Callan

Margaret DeMagistris

Scott MacRae

Keith Nehrke

Krystel R Huxlin

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to critically test the hypothesis that mitochondrial pyruvate carrier (MPC) function is essential for maintenance of the corneal myofibroblast phenotype in vitro and in vivo.

Methods: Protein and mRNA for canonical profibrotic markers were assessed in cultured cat corneal myofibroblasts generated via transforming growth factor (TGF)-β1 stimulation and treated with either the thiazolidinedione (TZD) troglitazone or the MPC inhibitor alpha-cyano-beta-(1-phenylindol-3-yl) acrylate (UK-5099). RNA sequencing was used to gain insight into signaling modules related to instructive, permissive, or corollary changes in gene expression following treatment. A feline photorefractive keratectomy (PRK) model of corneal wounding was used to test the efficacy of topical troglitazone at reducing α-smooth muscle actin (SMA)-positive staining when applied 2 to 4 weeks postoperatively, during peak fibrosis.

Results: Troglitazone caused cultured myofibroblasts to adopt a fibroblast-like phenotype through a noncanonical, peroxisome proliferator-activated receptor (PPAR)-γ-independent mechanism. Direct MPC inhibition using UK-5099 recapitulated this effect, but classic inhibitors of oxidative phosphorylation (OXPHOS) did not. Gene Set Enrichment Analysis (GSEA) of RNA sequencing data converged on energy substrate utilization and the Mitochondrial Permeability Transition pore as key players in myofibroblast maintenance. Finally, troglitazone applied onto an established zone of active fibrosis post-PRK significantly reduced stromal α-SMA expression.

Conclusions: Our results provide empirical evidence that metabolic remodeling in myofibroblasts creates selective vulnerabilities beyond simply mitochondrial energy production, and that these are critical for maintenance of the myofibroblast phenotype. For the first time, we provide proof-of-concept data showing that this remodeling can be exploited to treat existing corneal fibrosis via inhibition of the MPC.

References

Planaguma A, Claria J, Miquel R, Lopez-Parra M, Titos E, Masferrer J . The selective cyclooxygenase-2 inhibitor SC-236 reduces liver fibrosis by mechanisms involving non-parenchymal cell apoptosis and PPARgamma activation. FASEB J. 2005; 19(9):1120-2. DOI: 10.1096/fj.04-2753fje. View

Chaurasia S, Kaur H, de Medeiros F, Smith S, Wilson S . Dynamics of the expression of intermediate filaments vimentin and desmin during myofibroblast differentiation after corneal injury. Exp Eye Res. 2009; 89(2):133-9. PMC: 2716066. DOI: 10.1016/j.exer.2009.02.022. View

Jester J, Brown D, Pappa A, Vasiliou V . Myofibroblast differentiation modulates keratocyte crystallin protein expression, concentration, and cellular light scattering. Invest Ophthalmol Vis Sci. 2012; 53(2):770-8. PMC: 3317419. DOI: 10.1167/iovs.11-9092. View

Musso G, Cassader M, Paschetta E, Gambino R . Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis. JAMA Intern Med. 2017; 177(5):633-640. PMC: 5470366. DOI: 10.1001/jamainternmed.2016.9607. View

McCommis K, Hodges W, Brunt E, Nalbantoglu I, McDonald W, Holley C . Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatology. 2016; 65(5):1543-1556. PMC: 5397348. DOI: 10.1002/hep.29025. View

Lipshitz I, Loewenstein A, Varssano D, Lazar M . Late onset corneal haze after photorefractive keratectomy for moderate and high myopia. Ophthalmology. 1997; 104(3):369-73; discussion 373-4. DOI: 10.1016/s0161-6420(97)30306-6. View

Kivanany P, Grose K, Tippani M, Su S, Petroll W . Assessment of Corneal Stromal Remodeling and Regeneration after Photorefractive Keratectomy. Sci Rep. 2018; 8(1):12580. PMC: 6105640. DOI: 10.1038/s41598-018-30372-2. View

Jester J . Corneal crystallins and the development of cellular transparency. Semin Cell Dev Biol. 2007; 19(2):82-93. PMC: 2275913. DOI: 10.1016/j.semcdb.2007.09.015. View

Gale E . Lessons from the glitazones: a story of drug development. Lancet. 2001; 357(9271):1870-5. DOI: 10.1016/S0140-6736(00)04960-6. View

10.

Hindman H, DeMagistris M, Callan C, McDaniel T, Bubel T, Huxlin K . Impact of topical anti-fibrotics on corneal nerve regeneration in vivo. Exp Eye Res. 2019; 181:49-60. PMC: 6443430. DOI: 10.1016/j.exer.2019.01.017. View

11.

Nigdelioglu R, Hamanaka R, Meliton A, OLeary E, Witt L, Cho T . Transforming Growth Factor (TGF)-β Promotes de Novo Serine Synthesis for Collagen Production. J Biol Chem. 2016; 291(53):27239-27251. PMC: 5207151. DOI: 10.1074/jbc.M116.756247. View

12.

Fuest M, Jhanji V, Yam G . Molecular and Cellular Mechanisms of Corneal Scarring and Advances in Therapy. Int J Mol Sci. 2023; 24(9). PMC: 10178104. DOI: 10.3390/ijms24097777. View

13.

Milam J, Keshamouni V, Phan S, Hu B, Gangireddy S, Hogaboam C . PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007; 294(5):L891-901. PMC: 5926773. DOI: 10.1152/ajplung.00333.2007. View

14.

Huxlin K, Hindman H, Jeon K, Buhren J, MacRae S, DeMagistris M . Topical rosiglitazone is an effective anti-scarring agent in the cornea. PLoS One. 2013; 8(8):e70785. PMC: 3733781. DOI: 10.1371/journal.pone.0070785. View

15.

Ung C, Onoufriadis A, Parsons M, McGrath J, Shaw T . Metabolic perturbations in fibrosis disease. Int J Biochem Cell Biol. 2021; 139:106073. DOI: 10.1016/j.biocel.2021.106073. View

16.

Mohan R, Hutcheon A, Choi R, Hong J, Lee J, Mohan R . Apoptosis, necrosis, proliferation, and myofibroblast generation in the stroma following LASIK and PRK. Exp Eye Res. 2003; 76(1):71-87. DOI: 10.1016/s0014-4835(02)00251-8. View

17.

Ramstead A, Wallace J, Lee S, Bauer K, Tang W, Ekiz H . Mitochondrial Pyruvate Carrier 1 Promotes Peripheral T Cell Homeostasis through Metabolic Regulation of Thymic Development. Cell Rep. 2020; 30(9):2889-2899.e6. PMC: 7170217. DOI: 10.1016/j.celrep.2020.02.042. View

18.

Harrison S, Alkhouri N, Davison B, Sanyal A, Edwards C, Colca J . Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study. J Hepatol. 2019; 72(4):613-626. DOI: 10.1016/j.jhep.2019.10.023. View

19.

Bernardi P, Rasola A, Forte M, Lippe G . The Mitochondrial Permeability Transition Pore: Channel Formation by F-ATP Synthase, Integration in Signal Transduction, and Role in Pathophysiology. Physiol Rev. 2015; 95(4):1111-55. PMC: 4600949. DOI: 10.1152/physrev.00001.2015. View

20.

Sautchuk R, Kalicharan B, Escalera-Rivera K, Jonason J, Porter G, Awad H . Transcriptional regulation of cyclophilin D by BMP/Smad signaling and its role in osteogenic differentiation. Elife. 2022; 11. PMC: 9191891. DOI: 10.7554/eLife.75023. View